Jacob Johnson
Stock Analyst at Stephens & Co.
(3.20)
# 1,162
Out of 4,412 analysts
66
Total ratings
48.15%
Success rate
0.99%
Average return
Main Sectors:
19 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MXCT MaxCyte | Reiterates: Overweight | $11 | $3.71 | +196.50% | 5 | Apr 23, 2024 | |
| CTLT Catalent | Reiterates: Equal-Weight | $64 | $55.92 | +13.56% | 4 | Apr 4, 2024 | |
| STVN Stevanato Group | Reiterates: Overweight | $38 | $27.54 | +37.98% | 2 | Mar 25, 2024 | |
| CYRX Cryoport | Reiterates: Equal-Weight | $17 | $16.38 | +3.79% | 3 | Mar 13, 2024 | |
| CDMO Avid Bioservices | Maintains: Overweight | $15 → $12 | $7.35 | +63.27% | 5 | Mar 11, 2024 | |
| CERS Cerus | Reiterates: Equal-Weight | $2.5 | $1.71 | +46.20% | 2 | Mar 7, 2024 | |
| STE STERIS | Reiterates: Overweight | $250 | $203.90 | +22.61% | 4 | Feb 9, 2024 | |
| AZTA Azenta | Reiterates: Equal-Weight | $70 | $52.18 | +34.15% | 4 | Feb 8, 2024 | |
| TECH Bio-Techne | Maintains: Overweight | $92 → $87 | $64.06 | +35.81% | 7 | Feb 2, 2024 | |
| WST West Pharmaceutical Services | Maintains: Overweight | $420 → $390 | $360.43 | +8.20% | 8 | Oct 27, 2023 | |
| MASS 908 Devices | Reiterates: Overweight | $14 | $5.67 | +146.91% | 2 | Sep 25, 2023 | |
| LFCR Lifecore Biomedical | Maintains: Equal-Weight | $8 → $9 | $6.60 | +36.47% | 3 | Sep 1, 2023 | |
| NEO NeoGenomics | Upgrades: Overweight | $16 → $18 | $14.14 | +27.30% | 4 | Aug 21, 2023 | |
| RGEN Repligen | Maintains: Overweight | $180 → $200 | $166.58 | +20.06% | 3 | Aug 3, 2023 | |
| CDXS Codexis | Reiterates: Overweight | $6 | $2.66 | +125.56% | 2 | Jul 21, 2023 | |
| BLFS BioLife Solutions | Maintains: Overweight | $27 → $29 | $17.53 | +65.43% | 3 | Jul 17, 2023 | |
| TKNO Alpha Teknova | Maintains: Overweight | $22 → $15 | $1.73 | +767.05% | 3 | Aug 11, 2022 | |
| LGND Ligand Pharmaceuticals | Maintains: Overweight | $153 → $130 | $70.57 | +84.21% | 1 | May 16, 2022 | |
| CRL Charles River Laboratories International | Initiates: Overweight | $377 | $229.03 | +64.61% | 1 | Apr 7, 2022 |
MaxCyte
Apr 23, 2024
Reiterates: Overweight
Price Target: $11
Current: $3.71
Upside: +196.50%
Catalent
Apr 4, 2024
Reiterates: Equal-Weight
Price Target: $64
Current: $55.92
Upside: +13.56%
Stevanato Group
Mar 25, 2024
Reiterates: Overweight
Price Target: $38
Current: $27.54
Upside: +37.98%
Cryoport
Mar 13, 2024
Reiterates: Equal-Weight
Price Target: $17
Current: $16.38
Upside: +3.79%
Avid Bioservices
Mar 11, 2024
Maintains: Overweight
Price Target: $15 → $12
Current: $7.35
Upside: +63.27%
Cerus
Mar 7, 2024
Reiterates: Equal-Weight
Price Target: $2.5
Current: $1.71
Upside: +46.20%
STERIS
Feb 9, 2024
Reiterates: Overweight
Price Target: $250
Current: $203.90
Upside: +22.61%
Azenta
Feb 8, 2024
Reiterates: Equal-Weight
Price Target: $70
Current: $52.18
Upside: +34.15%
Bio-Techne
Feb 2, 2024
Maintains: Overweight
Price Target: $92 → $87
Current: $64.06
Upside: +35.81%
West Pharmaceutical Services
Oct 27, 2023
Maintains: Overweight
Price Target: $420 → $390
Current: $360.43
Upside: +8.20%
908 Devices
Sep 25, 2023
Reiterates: Overweight
Price Target: $14
Current: $5.67
Upside: +146.91%
Lifecore Biomedical
Sep 1, 2023
Maintains: Equal-Weight
Price Target: $8 → $9
Current: $6.60
Upside: +36.47%
NeoGenomics
Aug 21, 2023
Upgrades: Overweight
Price Target: $16 → $18
Current: $14.14
Upside: +27.30%
Repligen
Aug 3, 2023
Maintains: Overweight
Price Target: $180 → $200
Current: $166.58
Upside: +20.06%
Codexis
Jul 21, 2023
Reiterates: Overweight
Price Target: $6
Current: $2.66
Upside: +125.56%
BioLife Solutions
Jul 17, 2023
Maintains: Overweight
Price Target: $27 → $29
Current: $17.53
Upside: +65.43%
Alpha Teknova
Aug 11, 2022
Maintains: Overweight
Price Target: $22 → $15
Current: $1.73
Upside: +767.05%
Ligand Pharmaceuticals
May 16, 2022
Maintains: Overweight
Price Target: $153 → $130
Current: $70.57
Upside: +84.21%
Charles River Laboratories International
Apr 7, 2022
Initiates: Overweight
Price Target: $377
Current: $229.03
Upside: +64.61%